ATNM (Actinium Pharmaceuticals Inc) Return on Sales by Gross Profit

Patent protection for radiopharmaceuticals used in bone marrow transplants provides Actinium Pharmaceuticals (ATNM) with a stable revenue stream. The commercialization strategy for Iomab-B in leukemia and active late-stage trials of targeted conjugates are driving growth. The gross margin share on GURU.Markets is based on these successes, where 96.90 forms the current metric, determining the efficiency of the business's direct cost coverage.
Analytical breakdowns and data insights for company actiniumpharma.com (ATNM)

The development of a unique radiotherapy for blood cancer provides Actinium Pharmaceuticals (ATNM) with exceptional market leverage and future pricing power. Gross margin measures the portion of revenue minus direct production costs, reflecting the efficiency of the operating model, which allows for an assessment of the gross profit margin as an indicator of the company's ability to generate profit from each unit of the drug sold.